Profile data is unavailable for this security.
About the company
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
- Revenue in USD (TTM)4.00k
- Net income in USD-5.46m
- Incorporated1992
- Employees4.00
- LocationTitan Pharmaceuticals IncSUITE 505, 400 OYSTER POINT BLVDSAN FRANCISCO 94080United StatesUSA
- Phone+1 (415) 244-4990
- Fax+1 (650) 244-4956
- Websitehttps://www.titanpharm.com/
More ▼
Mergers & acquisitions
| Acquired company | TTNP:NAQ since announced | Transaction value |
|---|---|---|
| KE Sdn Bhd | -24.35% | -- |
Data delayed at least 15 minutes, as of Nov 25 2024 20:50 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 2.16m | 233.00 | 0.0145 | 0.0002 | 0.5586 | 0.0305 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Scisparc Ltd | 0.00 | -6.96m | 2.54m | 3.00 | -- | 7.05 | -- | -- | -1.22 | -1.51 | 0.00 | 0.0344 | 0.00 | -- | -- | 0.00 | -92.51 | -69.39 | -152.41 | -111.07 | -- | -- | -- | -527.17 | -- | -- | 0.9371 | -- | 113.73 | -- | -97.61 | -- | -- | -- |
| CYANOTECH CORP | 23.30m | -5.45m | 2.72m | 77.00 | -- | 0.2510 | -- | 0.1167 | -0.7939 | -0.7939 | 3.40 | 1.36 | 0.896 | 2.15 | 15.42 | 302,532.50 | -20.98 | -3.46 | -32.30 | -4.46 | 22.66 | 34.54 | -23.41 | -3.58 | 0.307 | -7.00 | 0.42 | -- | -0.4616 | -5.24 | -53.11 | -- | -6.42 | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 2.76m | -- | -- | -- | 1.82 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
| Processa Pharmaceuticals Inc | 0.00 | -11.53m | 2.81m | 13.00 | -- | 0.8587 | -- | -- | -4.86 | -4.86 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -176.99 | -84.35 | -209.96 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0022 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| Scorpius Holdings Inc | 10.04m | -29.66m | 2.86m | 82.00 | -- | 0.0812 | -- | 0.2846 | -107.62 | -101.17 | 5.25 | 8.12 | 0.1725 | -- | 16.55 | 122,491.30 | -53.23 | -39.37 | -69.92 | -43.18 | 61.92 | -- | -308.58 | -1,068.21 | 0.6007 | -27.31 | 0.3146 | -- | 1,789.58 | 3.84 | 1.96 | -- | 27.32 | -- |
| Universe Pharmaceuticals Inc | 26.73m | -18.55m | 3.04m | 225.00 | -- | 0.0169 | -- | 0.1138 | -76.44 | -76.44 | 110.26 | 110.02 | 0.4462 | 6.13 | 1.68 | 118,781.90 | -30.97 | 5.31 | -48.85 | 7.07 | 28.27 | 46.26 | -69.40 | 6.25 | 1.46 | -0.6939 | 0.1958 | 0.00 | -19.52 | 2.53 | 29.46 | -- | -21.17 | -- |
| NovaBay Pharmaceuticals Inc | 11.20m | -16.44m | 3.33m | 24.00 | -- | 2.85 | -- | 0.2971 | -53.22 | -53.40 | 7.77 | 0.2195 | 1.34 | 2.22 | 13.83 | 466,625.00 | -119.49 | -61.51 | -196.48 | -83.89 | 60.67 | 59.99 | -89.25 | -86.47 | 0.9103 | -- | 0.0454 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
| Titan Pharmaceuticals Inc | 4.00k | -5.46m | 3.39m | 4.00 | -- | 0.8782 | -- | 847.95 | -6.59 | -6.59 | 0.0049 | 4.37 | 0.0016 | -- | 0.1702 | 1,000.00 | -211.58 | -96.80 | -368.99 | -156.65 | -- | -- | -136,525.00 | -406.26 | -- | -309.96 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| China Pharma Holdings Inc | 5.54m | -4.74m | 3.71m | 231.00 | -- | 0.5584 | -- | 0.6684 | -0.3958 | -0.3958 | 0.4119 | 0.3655 | 0.3848 | 2.38 | 15.81 | 24,002.68 | -32.92 | -29.66 | -55.81 | -55.25 | -34.34 | 6.47 | -85.56 | -73.09 | 0.2605 | -27.44 | 0.377 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| Sonoma Pharmaceuticals Inc | 13.55m | -3.69m | 3.82m | 172.00 | -- | 0.7328 | -- | 0.2817 | -4.91 | -4.91 | 16.95 | 4.00 | 0.9917 | 3.11 | 5.04 | 78,761.63 | -26.98 | -29.36 | -35.49 | -40.65 | 38.52 | 38.00 | -27.21 | -30.93 | 2.84 | -- | 0.0151 | -- | -4.05 | -7.66 | 6.13 | -- | -29.84 | -- |
| Silo Pharma Inc | 72.12k | -3.71m | 3.86m | 3.00 | -- | 0.5759 | -- | 53.48 | -1.16 | -1.19 | 0.022 | 1.51 | 0.0082 | -- | -- | 24,040.00 | -42.31 | -24.90 | -46.92 | -26.39 | 91.90 | 82.79 | -5,149.53 | -2,757.85 | -- | -- | 0.00 | -- | 0.00 | -- | 7.07 | -- | -- | -- |
| Tian'an Pharmaceutical Co Ltd | 10.65m | 3.14m | 4.16m | -- | 0.0232 | 0.005 | 1.14 | 0.3906 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| AgriFORCE Growing Systems Ltd | 57.60k | -17.40m | 4.61m | 7.00 | -- | 0.5824 | -- | 80.06 | -1.85 | -1.85 | 0.0015 | 0.0671 | 0.0041 | 2.01 | 1.17 | 8,228.57 | -123.72 | -78.95 | -192.19 | -109.86 | 17.86 | -- | -30,208.85 | -243,182.50 | 0.6002 | -1.64 | 0.1458 | -- | -- | -- | 8.85 | -- | 48.61 | -- |
Data as of Nov 25 2024. Currency figures normalised to Titan Pharmaceuticals Inc's reporting currency: US Dollar USD
1.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 30 Sep 2024 | 11.07k | 1.21% |
| UBS Securities LLCas of 30 Sep 2024 | 4.77k | 0.52% |
| Tower Research Capital LLCas of 30 Sep 2024 | 743.00 | 0.08% |
| MCF Advisors LLCas of 30 Sep 2024 | 165.00 | 0.02% |
| Group One Trading LLCas of 30 Sep 2024 | 12.00 | 0.00% |
| BofA Securities, Inc.as of 30 Sep 2024 | 11.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2024 | 7.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 6.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 4.00 | 0.00% |
| American Portfolios Advisors, Inc.as of 30 Sep 2024 | 3.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
